Working… Menu

Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00057031
Recruitment Status : Unknown
Verified February 2005 by Novacea.
Recruitment status was:  Active, not recruiting
First Posted : April 1, 2003
Last Update Posted : November 1, 2006
Information provided by:

Brief Summary:
The purpose of this study is to determine the safety and efficacy of DN-101 (calcitriol) in patients with myelodysplastic syndrome who are dependent on repeat blood transfusions.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndrome Drug: DN-101 (calcitriol) Phase 2

Detailed Description:

DN-101 is an experimental drug that has not been approved by the Food and Drug Administration (FDA). It is a newly formulated pill that contains high amounts of calcitriol, a naturally occurring hormone and the biologically active form of vitamin D. The natural vitamin D found in dairy products or in typical vitamin pills, must be chemically changed by the liver and kidney into calcitriol before it is biologically active. The body normally uses small amounts of calcitriol to regulate its blood calcium levels. However, for any possible therapeutic effect, MDS patients require much higher levels of calcitriol than the body can produce from dietary vitamin D. DN-101 provides MDS patients with high doses of calcitriol in a pill form.

Laboratory studies have demonstrated evidence supporting the use of calcitriol in MDS. High dose calcitriol slows the growth of leukemic cells (cancerous cells) and increases the growth of normal bone marrow cells. Some patients with MDS may have low levels of calcitriol in their bone marrow.

Clinical study results in patients with MDS have been mixed- some positive and some negative results. Elevated calcium in the blood occurred frequently and prevented the use of higher, more potentially therapeutic doses.

Novacea tested a new formulation of calcitriol, DN-101, in a Phase 1 study. In that study the maximum tolerated dose of DN-101 that did not cause high blood calcium levels when given weekly for several months was determined. That dose is within the range that is potentially therapeutic for MDS patients and will be used in this MDS study.

The purposes of this study are to determine if HDPA DN-101 treatment:

  • increases the number of red blood cells, white blood cells, and platelets in the blood
  • reduces the number of blood transfusions
  • reduces the number of serious infections requiring antibiotics
  • reduces the number of serious bleeding events
  • improves fatigue

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 46 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Open Label Study of the Safety and Efficacy of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome
Study Start Date : November 2002
Study Completion Date : March 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Calcitriol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Diagnosis of low or intermediate-1 risk MDS
  • Dependent on monthly blood transfusions
  • No cancer within the last 5 years (cured skin cancer is allowed)
  • No heart attack or stroke within the last 6 months
  • No kidney stones within the last 5 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00057031

Layout table for location information
United States, Alabama
Clinical Research Consultants, Inc.
Hoover, Alabama, United States, 35216
United States, California
University of California, San Francisco
San Francisco, California, United States, 94143
United States, Florida
James A. Haley Veterans Hospital
Tampa, Florida, United States, 33612
United States, Illinois
Rush Cancer Institute MDS Center
Chicago, Illinois, United States, 60612
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
United States, Ohio
The Cleveland Clinic Foundation, Taussig Cancer Center
Cleveland, Ohio, United States, 44195
United States, Oregon
Oregon Health Sciences University
Portland, Oregon, United States, 97201
United States, Tennessee
Boston Baskin Cancer Group
Memphis, Tennessee, United States, 38104
United States, Texas
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Layout table for additonal information Identifier: NCT00057031    
Other Study ID Numbers: DN101-003
First Posted: April 1, 2003    Key Record Dates
Last Update Posted: November 1, 2006
Last Verified: February 2005
Keywords provided by Novacea:
myelodysplastic syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Growth Substances
Bone Density Conservation Agents